Navigation Links
Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building
Date:4/3/2008

ople's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at http://www.roche.com.

All trademarks used or mentioned in this release are legally protected by law.

For further information please contact:

Amy Berry

Roche Molecular Diagnostics

Communications

Phone: 925-730-8028

email: amy.berry@contractors.roche.com


'/>"/>
SOURCE Roche Molecular Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Roche Extends Tender Offer for Ventana
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. Med Ad News Honors Roche as Company of the Year
8. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... emerging diseases and biodiversity loss requires evolutionary thinking, ... Science Express that was co-authored by Bruce ... Agriculture and Life Sciences. , For the first ... reviewed progress in addressing a broad set of ... approaches that consider evolutionary histories and the likelihood ...
(Date:9/29/2014)... Albany,NY (PRWEB) September 29, 2014 Transparency ... (by Synthesis - SPPS, LPPS, HPPS, by Application - ... Innovative & Generic and by Delivery) - Global Industry ... 2018’, states that the global peptide therapeutics market was ... reach US$25.4 billion by 2018 at an 8.7% CAGR. ...
(Date:9/29/2014)... SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life ... products for advanced microarray diagnostics, is pleased to announce ... of the Board of Directors of SQI, replacing ... as a Director on the Board and will continue ... "We are very pleased to have Mr. Winkley assume ...
(Date:9/29/2014)... ZIONA, Israel , September 29, ... stage company developing novel immunomodulators for severe infections, today ... ( BARDA ) has awarded Atox Bio with a ... for the development of AB103 to treat Necrotizing Soft ... and public health threats that end in sepsis. ...
Breaking Biology Technology:Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3SQI Diagnostics Announces New Chairman of Board of Directors 2Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2
... , , SAN FRANCISCO, Aug. 4 Nile ... the development of novel therapeutics for heart failure patients, today announced ... of its lead product, CD-NP, for the treatment of acute heart ... study is designed to provide additional information on the safety and ...
... /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) ... Hausman, M.D., as Vice President, Clinical Development at Oncothyreon. ... planning and implementing the clinical development program for the ... is an experienced oncologist who brings an extensive background ...
... , PALO ALTO, Calif., August ... antiviral therapies, announced today that it has licensed the exclusive ... Stanford University. This technology, discovered in the lab of Stanford ... focused on a variety of novel targets, including key features ...
Cached Biology Technology:Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure 2Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure 3Oncothyreon appoints Diana Hausman as Vice President of Clinical Development 2Oncothyreon appoints Diana Hausman as Vice President of Clinical Development 3Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University 2
(Date:9/29/2014)... Energy Joint Genome Institute (DOE JGI), a DOE ... 32 new projects have been selected for the ... lakes to Caribbean waters, and from plant root ... in forested watersheds, the CSP 2015 projects portfolio ... be extracted. , "These projects catalyze JGI,s ...
(Date:9/29/2014)... who lived 2,330 years ago in the southernmost tip of ... when his DNA profile is one of the ,earliest diverged, ... region where modern humans are believed to have originated roughly ... ,mitochondrial DNA, was sequenced to provide clues to early modern ... that we all come from Africa, and helps us map ...
(Date:9/29/2014)... Ill. Scientists have discovered a previously unknown ... grow and, in the case of estrogen-positive breast ... work reveals new targets for breast cancer therapy ... the most aggressive treatment. , The University of ... Oncogene . , Estrogen pre-activates the unfolded-protein ...
Breaking Biology News(10 mins):2015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3Scientists discover a new role for estrogen in the pathology of breast cancer 2
... Hopkins researchers have created a synthetic protein that, when activated ... body where cancer, arthritis and other serious medical disorders can ... type of diagnostic imaging technology and may someday serve as ... where signs of disease have been found. In a study ...
... mood for food can be changed by a restaurant,s choice ... calorie intake, according to a new study., "When we did ... music and lighting led diners to eat 175 fewer calories ... Wansink, professor of marketing and director of Cornell University,s Food ...
... FARMINGTON, Conn., Aug. 29, 2012 /PRNewswire-iReach/ -- The biobanking market ... new drug and treatment development for specific diseases. The ... and is projected to increase by 30% between 2010 and ... Private sector biobanks will experience the greatest increase with growth ...
Cached Biology News:Collagen-seeking synthetic protein could lead doctors to tumor locations 2Collagen-seeking synthetic protein could lead doctors to tumor locations 3Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 2Global Biobanking Market Projected to Increase by 30% to Reach $183 Billion by 2015 3
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
WIF-1 (N-20)...
VEGF Receptor-2, phospho-specific (Tyr996)...
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Biology Products: